Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03212404
Title	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Checkpoint Therapeutics, Inc.
Indications	non-Hodgkin lymphoma endometrial carcinoma Hodgkin's lymphoma renal pelvis transitional cell carcinoma melanoma renal cell carcinoma lung small cell carcinoma Merkel cell carcinoma peritoneal mesothelioma ureter transitional cell carcinoma colorectal cancer lung non-small cell carcinoma malignant pleural mesothelioma head and neck squamous cell carcinoma transitional cell carcinoma skin squamous cell carcinoma urethra transitional cell carcinoma
Therapies	Cosibelimab
Age Groups:	adult \| senior
Covered Countries	POL \| NZL \| FRA \| ESP \| AUS